Atazanavir-d6, CAS 1092540-50-5

Product Description: Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Applications: COVID-19-anti-virus

Formula: C38H46D6N6O7

References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604./[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212./[4]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.

CAS Number: 1092540-50-5

Molecular Weight: 710.89

Compound Purity: 99.28

Research Area: Infection; Cancer

Solubility: 10 mM in DMSO

Target: Cytochrome P450;Endogenous Metabolite;HIV;HIV Protease;Isotope-Labeled Compounds;P-glycoprotein;SARS-CoV

• Artikelnummer: MEXHY-17367S4-500UG
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-17367S4-500UG
• Verpackungseinheit: 500 μg
• Mengeneinheit: STK